Skip to content
Search

Latest Stories

Submit Guest Post

Dhamecha acquires TRS Leyton depot

Dhamecha acquires TRS Leyton depot

By Jaimin Solanki

ONE of the UK’s largest independent wholesalers, Dhamecha Cash & Carry, has acquired a depot in east London from rival TRS.


The site in Leyton will be Dha­mecha’s 10th unit in the country; it currently operates seven sites in London and branches in Birming­ham and Leicester.

According to reports, the com­pletion of the deal is expected to take place by the end of February.

Dhamecha Group bought the site from private equity firm Expo­nent, which acquired TRS and East End Foods in 2019. Exponent created a new business called Vi­brant Foods to bring the TRS and East End businesses together.

Chief executive of the group, Pradip Dhamecha, said the deal included a provision to sell a se­lection of TRS and East End-branded products.

He added that they are plan­ning to fully refurbish the site over several months before opening.

“We have been in discussions with TRS and their owners, Vi­brant Foods, for a period of time and are excited to make this addi­tion to our group. The depot will close for several months for reno­vation and refurbishment. We look forward to welcoming both new and existing customers when the depot re-opens later in 2021,” said Dhamecha.

“As part of the acquisition of the new depot, we are also delighted that we will be able to provide a good selection of TRS and East End branded products in our depots. As we expand our footprint, we will con­tinue to build on our reputa­tion for excellent service, com­petitive pricing and great stock availability. We look forward to working closely with all our cus­tomers, suppliers and colleagues.”

Dhamecha Cash & Carry was established in 1976 by three brothers KR, SR and JR Dhamecha, when they opened their first unit in Wem­bley. It has around 14,000 trade-only customers and offers a range of more than 12,000 branded products.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less